ViatrisXSWX:VTRS +0.62%60 Buyback Yield % is 1.71 as of Jul. 02, 2026, which is 17% below its 10-year median of 2.05. GuruFocus rates XSWX:VTRS with a GF Score™ of 60/100 and a GF Value™ of CHF8.89. The stock has 8 warning signs investors should review. Among 293 Drug Manufacturers companies, Viatris ranks better than 88.74% on this metric.
Buyback yield is the net repurchase of shares outstanding over the market capital of the company. It is a measure of shareholder return.
The historical data trend for Viatris's Buyback Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XSWX:VTRS vs NBIX, UTHR, ELAN: Buyback Yield % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Viatris's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Viatris Buyback Yield % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Viatris's Buyback Yield % distribution charts can be found below:
* The bar in red indicates where Viatris's Buyback Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Viatris (XSWX:VTRS) has a Buyback Yield % of 1.71 as of Jul. 02, 2026. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Viatris and its competitors. This is 17% below median its historical median of 2.05. According to the industry distribution chart, Viatris ranks #33 out of 293 companies in the Drug Manufacturers industry, placing it in the top 11.3%.
Is Viatris' Buyback Yield % too high?
Viatris' current Buyback Yield % of 1.71 is 17% below median its 10-year median of 2.05. Based on the distribution chart, Viatris ranks #33 out of 293 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Viatris has a GF Score™ of 60/100, reflecting its overall financial health beyond just this single metric.
How does Viatris' Buyback Yield % compare to NBIX and UTHR?
According to the Drug Manufacturers industry distribution chart, Viatris ranks #33 out of 293 companies for Buyback Yield %. This places Viatris in the top 11% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Buyback Yield % for a Drug Manufacturers company?
A good Buyback Yield % depends on the Drug Manufacturers industry context. However, Buyback Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Buyback Yield % mean?
A high Buyback Yield % can signal that a stock is expensive relative to its fundamentals. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Viatris and its competitors. Viatris's current Buyback Yield % is 1.71, which is 17% below median its own 10-year median of 2.05. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Viatris stock overvalued right now?
Viatris (XSWX:VTRS) has a current Buyback Yield % of 1.71. The stock's GF Value™ is CHF8.89, compared to a current price of CHF13.06 — trading 46.9% above its estimated fair value. The current Buyback Yield % is 1.71, which is 17% below median its 10-year median of 2.05. Viatris' overall GF Score™ is 60/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Buyback Yield % calculated?
Buyback Yield % is calculated from a company's financial statements. For Viatris (XSWX:VTRS), the current Buyback Yield % is 1.71 as of Jul. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Viatris (XSWX:VTRS) Overvalued in 2026?
Based on GuruFocus' analysis, Viatris stock appears to be overvalued.
The current stock price of CHF13.06 is trading 46.9% above its estimated GF Value™ of CHF8.89.
Key valuation signals for XSWX:VTRS:
Buyback Yield %: 1.71 (17% below median its 10-year median of 2.05)
GF Value™: CHF8.89 vs. price of CHF13.06 (46.9% above fair value)
No single metric tells the full story. See the XSWX:VTRS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Viatris was formed in November 2020 through the combination of Upjohn, a wholly owned subsidiary of Pfizer that specialized in off-patent drugs, and Mylan, a global pharmaceutical manufacturer that focused on generic and specialty drugs. By joining forces, Viatris became one of the largest generic drug manufacturers in the world, servicing over 165 countries. Generics (commoditized and complex) and biosimilars make up roughly 40% of Viatris' total sales. The remaining 60% of sales are derived from its portfolio of legacy products, which includes Lipitor, Norvasc, Lyrica, and Viagra. While it covers more than 10 major therapeutic areas, Viatris has identified dermatology, ophthalmology, and gastroenterology as its three key areas of focus for future innovations.
60GF Score
Get the complete analysis for XSWX:VTRS
Buyback Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:VTRS has been successfully added to your 
